Ongoing
Optimising Outcomes at Critical Points in the Cascade of HIV Care in Ontario
Learn MoreReporting
Immunogenicity outcomes in people living with HIV following vaccination for COVID-19 (HIV-COV)
Learn MoreOngoing
The impact of COVID-19 on persons with HIV in Canada: Data from the HIV/HCV co-infection/CCC (CTN 222) and HIV aging cohorts (CTN 314)
Learn MoreReporting
Electronic capture through the Opal patient portal of a patient-reported measure of barriers to antiretroviral therapy adherence: a mixed method type 3 hybrid pilot study at a large Montreal HIV clinic
Learn MoreEnrolling
A multicenter, randomized controlled trial of the efficacy, safety and immunogenicity of the 9-valent human papillomavirus (HPV) vaccination in preventing recurrence of high-grade anal dysplasia in HIV-positive men who have sex with men (MSM)
Learn MoreOngoing
Integrating cognitive-behavioural therapy for social anxiety disorder with HIV risk reduction counselling for HIV-negative gay and bisexual men who are at high risk for HIV
Learn MoreCompleted
Transgender women removing healthcare barriers to engagement in the HIV prevention and care cascades
Learn MoreOngoing
Preventing HIV by targeting the immune system instead of the virus
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
